An arrhythmia is a problem with the speed or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm. A heartbeat that is too fast is called tachycardia. A heartbeat that is too slow is called bradycardia. Most arrhythmias are harmless, but some can be serious or even life threatening. When the heart rate is too slow, too fast, or irregular, the heart may not be able to pump enough blood to the body. Lack of blood flow can damage the brain, heart, and other organs.
Stereotaxis, Inc. announced today that it launched the Odyssey Interventional Network, a training and educational video sharing web portal for the global cardiovascular community. The portal will showcase innovative electrophysiology (EP) and interventional cardiology (IC) procedures from leading centers around the world.
CyDex Pharmaceuticals, Inc. today announced a mutual decision with Prism Pharmaceuticals to terminate their existing joint development agreement on novel Captisol-enabled® intravenous formulations of clopidogrel. This provides CyDex with full development and commercialization rights to the product candidate - an injectable formulation of clopidogrel. Clopidogrel is the active ingredient in PLAVIX®, an orally available antiplatelet drug, which currently is marketed by Bristol-Myers Squibb Company and Sanofi-Aventis, Inc.
Magnetecs Corporation, a designer and manufacturer of robotic systems for minimally invasive surgical procedures, today reported that human studies have commenced using the Company's Catheter Guidance Control and Imaging (CGCI) system for patients with arrhythmia, or irregular heart beat.
In a powerful demonstration of collective standing in the health care community, more than 40 organizations gathered on Capitol Hill to issue a call to action in reducing sudden cardiac arrest (SCA) deaths.
Scientists at the University of Bonn have altered cardiac muscle cells to make them controllable with light. They were thus able to use directed light to cause conditions such as arrhythmia in genetically modified mice. The method opens up completely new possibilities for researching the development of such arrhythmias. The study will be published in the upcoming edition of "Nature Methods".
CardioDx, a pioneer in the field of cardiovascular genomic diagnostics, today announced publication of results from the Personalized Risk Evaluation and Diagnosis In the Coronary Tree (PREDICT) trial in the Annals of Internal Medicine, the journal of the American College of Physicians.
Estech, a leading provider of minimally invasive cardiac surgery devices, today announced the launch of its COBRA Revolution™ Bipolar Clamp for use in surgical ablation procedures. The new instrument enables deep transmural lesion formation after a single application and is the only clamp to feature reversible jaws, which uniquely allows surgeons to follow anatomic contours, for unprecedented ease of use and efficiency.
Merck today announced that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, will be presented in oral plenary sessions at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which is taking place from Oct. 29 through Nov. 2 in Boston. Results for boceprevir in response-guided therapy strategies, which evaluated treatment durations shorter than current standard therapy, will be presented during the meeting.
Global Health Partner (STO:GHP) has acquired Stockholm Gastro Center, a specialist clinic with operations within medical gastroenterology and endoscopy located at Sophiahemmet in Stockholm. "The acquisition of Stockholm Gastro Center is a good complement to the obesity surgery business that we run at Kirurgkliniken and Bariatric Center Stockholm in Sophiahemmet's facilities. This is a combination of businesses that we also have at our clinics in Lund and Prague and where we see good coordination and expansion opportunities," says Per Båtelson, Global Health Partner's CEO.
During the recent Atrial Fibrillation Session of the Techno College at the European Association of Cardiac Thoracic Surgeons in Geneva, Switzerland, Professor Borut Gersak, Head of Cardiac Surgery from University Medical Center in Ljubljana, Slovenia challenged his audience of more than 1,000 medical professionals to think differently about existing atrial fibrillation surgical approaches.
Patients under age 45 had fewer major complications than older patients and comparable improvement after a medical procedure to treat irregular heartbeat, or arrhythmia, in a study reported in Circulation: Arrhythmia and Electrophysiology, an American Heart Association journal.
Stereotaxis, Inc. today announced that the U.S. Patent and Trademark Office granted the Company its 100th patent, a major intellectual property milestone. The 100th patent, U.S. patent No. 7,772,950, covers the "Method and Apparatus for Dynamic Magnetic Field Control Using Multiple Magnets." The 100th patent reflects Stereotaxis' ongoing commitment to innovate and protect its leading position in robotic solutions for interventional medicine.
An abrupt, fatal heart attack in a young athlete on the playing field is a tragedy destined to repeat itself over and over until more is understood about hypertrophic cardiomyopathy (HCM), a genetic disorder that is the most common cause of sudden death in young people but which affects people of all ages.
Relypsa, Inc., a biopharmaceutical company developing non-absorbed polymeric drugs, today announced positive results from the company's PEARL-HF study, a Phase 2 clinical trial of the company's lead compound, RLY5016. These data were presented by Dr. Bertram Pitt, Professor of Medicine Emeritus, Division of Medicine at the University of Michigan School of Medicine, during the Late-Breaking Clinical Trials Session in an oral presentation titled "The PEARL-HF (Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple-Dose To Evaluate the Effects of RLY5016 in Heart Failure Patients) Trial" at the 14th Annual Scientific Meeting of the Heart Failure Society of America held in San Diego, CA September 13-15, 2010.
An abrupt, fatal heart attack in a young athlete on the playing field is a tragedy destined to repeat itself over and over until more is understood about hypertrophic cardiomyopathy (HCM), a genetic disorder that is the most common cause of sudden death in young people but which affects people of all ages. So says a task force of cardiologists and cardiac biologists, headed by Thomas L. Force, M.D., James C. Wilson Professor of Medicine at Thomas Jefferson University, in the September 14th online edition of the journal Circulation.
Medtronic, Inc. today introduced the CareLink® Network for Heart Failure, an extension of the world's largest remote implantable cardiac device monitoring system, that will be available this fall for heart failure clinicians.
Stereotaxis, Inc. highlighted significant new additions to the body of evidence demonstrating exceptional clinical outcomes achieved with its Niobe® Magnetic Navigation System in ventricular tachycardia ablation.
The National Institutes of Health plans to spend $161.3 million over the next five years to expand the Pharmacogenomics Research Network (PGRN), a nationwide collaborative of scientists focused on understanding how genes affect a person's response to medicines.
MSD and Cardiome Pharma Corp. today announced that the intravenous (IV) formulation of BRINAVESS™ (vernakalant) has been granted marketing approval in the European Union (EU), Iceland and Norway for the conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults.
The European Society of Cardiology (ESC) today announces the release of new Clinical Practice Guidelines covering Atrial Fibrillation. These are the first guidelines to be prepared solely by the ESC on this very important topic.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.